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Abstract
Aim: To create an irreversible pulpitis gene signature from microarray data of healthy 
and inflamed dental pulps, followed by a bioinformatics approach using connectivity 
mapping to identify therapeutic compounds that could potentially treat pulpitis.
Methodology: The Gene Expression Omnibus (GEO) database, an international public 
repository of genomics data sets, was searched for human microarray datasets assessing 
pulpitis. An irreversible pulpitis gene expression signature was generated by differential 
expression analysis. The statistically significant connectivity map (ssCMap) method was 
used to identify compounds with a highly correlating gene expression pattern. qPCR 
was used to validate novel pulpitis genes. An ex vivo pulpitis model was used to test the 
effects of the compounds identified, and the level of inflammatory cytokines was meas-
ured with qPCR, ELISA and multiplex array. Means were compared using the t- test or 
ANOVA with the level of significance set at p ≤ .05.
Results: Pulpitis gene signatures were created using differential gene expression analysis 
at cutoff points p = .0001 and .000018. Top upregulated genes were selected as potential 
pulpitis biomarkers. Among these, IL8, IL6 and MMP9 were previously identified as pul-
pitis biomarkers. Novel upregulated genes, chemokine (C- C motif) ligand 21 (CCL21), 
metallothionein 1H (MT1H) and aquaporin 9 (AQP9) were validated in the pulp tissue of 
teeth clinically diagnosed with irreversible pulpitis using qPCR. ssCMap analysis identified 
fluvastatin (Statin) and dequalinium chloride (Quaternary ammonium) as compounds with 
the strongest correlation to the gene signatures (p = .0001). Fluvastatin reduced IL8, IL6, 
CCL21, AQP9 (p < .001) and MMP9 (p < .05) in the ex vivo pulpitis model, while dequalin-
ium chloride reduced AQP9 (p < .001) but had no significant effect on the other biomarkers.
Conclusions: AQP9, MT1H and CCL21 were identified and validated as novel biomark-
ers for pulpitis. Fluvastatin and dequalinium chloride identified by the ssCMap as poten-
tial therapeutics for pulpitis reduced selected pulpitis biomarkers in an ex vivo pulpitis 
model. In vivo testing of these licenced drugs is warranted.
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INTRODUCTION
The dental pulp responds to injury by mounting an inflamma-
tory response characterized by recruitment of immune cells 
and release of inflammatory mediators and cytokines lead-
ing to pulpitis (Hahn & Liewehr, 2007). Clinically, pulpitis 
is diagnosed as either, reversible; indicating that the inflam-
mation should resolve following appropriate management, or 
irreversible; indicating that the inflamed pulp is considered 
incapable of healing and for which root canal treatment is 
indicated (Levin et al., 2009). However, the clinical diagno-
sis for pulpitis is largely based on subjective symptoms and 
diagnostic methods that poorly correlate with the histological 
status of the dental pulp (Mejàre et al., 2012).
Attempts at improving the diagnosis of pulpitis using 
biomarkers have been suggested. Although limited by pulp 
accessibility for sampling, numerous studies have reported 
the use of biomarkers for pulpal diagnosis (Rechenberg et al., 
2016; Zanini et al., 2017; Zehnder et al., 2011). Various in-
flammatory cytokines and mediators that are differentially 
expressed in healthy and inflamed pulps have been suggested 
as potential biomarkers. In these studies, however, candidate 
biomarkers were often limited in number and chosen a pri-
ori by investigators. An alternative molecular analysis using 
microarray gene expression data of pulpitis and healthy pulps 
would provide a more comprehensive method for the selec-
tion of biomarkers. Mining such data, a pulpitis specific gene 
signature could be created using differential expression anal-
ysis to identify novel biomarkers. Furthermore, bioinformat-
ics platforms such as connectivity mapping (CMap) could be 
used to identify compounds that could potentially modify the 
pulpitis gene signature in favour of a healthy state.
Gene expression connectivity mapping (CMap) is an in-
novative bioinformatics platform, which uses a reference da-
tabase of gene expression profiles obtained from microarray 
experiments in cell lines treated with various drugs. The basic 
concept is to use a reference database containing drug- specific 
gene expression profiles and compare it with a disease- specific 
gene signature. Theoretically, these genes may be important 
for the induction of the phenotype of interest, therefore, sim-
ilar alteration of gene expression by any compound or drug 
identified would be predicted to induce the same phenotype. 
The technique is employed for drug repositioning approaches 
(Lamb, 2007) and further developed into the ‘statistically sig-
nificant connectivity map’ (ssCMap) by using statistical means 
to control for false connections between gene signature and 
reference profiles (Musa et al., 2018; Zhang & Gant, 2009). 
The ssCMap has been successfully applied to phenotypic 
targeting and predicting effective drugs for several diseases 
(Malcomson et al., 2016; Ramsey et al., 2013) and recently 
for induction of osteo/odontogenic phenotypes of dental pulp 
cells (Rankin et al., 2020). It was therefore hypothesized that 
connectivity mapping could be used to identify compounds or 
drugs that could reverse the gene signature in pulpitis from in-
flammation to a closer to healthy phenotype. The study aims to 
use differential gene expression analysis of microarray data of 
dental pulps clinically diagnosed with irreversible pulpitis and 
healthy controls to create a pulpitis gene signature to identify 
potential biomarkers and use ssCMap to identify therapeutic 




GEO databases were searched using the keywords: ‘dental 
pulp’, ‘pulpitis’, ‘inflammation of dental pulp’ and ‘irrevers-
ible pulpitis’. The search identified two studies, GSE92681 
and GSE77459. GSE92681 was excluded as it looked at long 
noncoding RNAs, which are not compatible with ssCMap. 
The Series Matrix Files (SMF) for GSE77459 data sets, 
which contain gene expression levels for all the probes used 
in the microarrays, were downloaded and opened in Microsoft 
Excel (Microsoft Corporation). The data sets (Galicia et al., 
2016) were for six healthy dental pulps from sound teeth and 
six dental pulps from carious teeth with a diagnosis of ir-
reversible pulpitis according to the American Association of 
Endodontists (AAE) classification (Levin et al., 2009). Two 
sample equal variance t- tests were performed on the gene 
expression levels measured in healthy and dental pulps diag-
nosed with irreversible pulpitis with Bonferroni post hoc test 
to control the expected number of false- positive differentially 
expressed genes (DEGs). Log2 fold changes were calculated 
by dividing the average expression level of the diseased sam-
ples by the average control for each gene, followed by taking 
the log2 of this value. If the log2 fold change was greater 
than 0, the genes were given a score of +1; if less than 0, they 
were given a score of −1.
ssCMap
The microarray was carried out on Affymetrix Human Gene 
2.1 ST Array (GPL17692) and in order to be compatible 
with ssCMap, the significantly differentially expressed genes 
were converted to GPL96 probe IDs as previously described 
(Rankin et al., 2020). Following conversion, two queries 
using two gene signatures were created by differential ex-
pression analysis, the first query gene signature was gener-
ated using significance level cut- off p = 1/N (p = .000018), 
where N is the total number of probes used in the array, and 
a second using a significance level cut- off p =  .0001, This 
cut- off p- value was aimed to control the expected number 
of false- positive DEGs. The empirical False Discovery Rate 
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(eFDR) was readily calculated once the number of signifi-
cant DEGs was obtained (Tsai et al., 2003; Zhang, 2011). 
Connectivity mapping was carried out with each signature 
gene query using Zhang and Gant's ssCMap (Zhang & Gant, 
2009) with default settings, which included a false connec-
tion tolerance of 1.0. Compounds with a significant posi-
tive connection score were considered for further analysis. 
To identify potential biomarkers, top expressed genes with a 
log2 fold change greater than 0.5859 (1.5- fold change) were 
considered.
Quantitative real- time PCR
Pulp tissue from patients diagnosed with symptomatic ir-
reversible pulpitis according to the AAE classification 
(Levin et al., 2009) and healthy pulps from sound third 
molars requiring extraction were obtained from patients 
attending the School of Dentistry, Queens University 
Belfast, Belfast, UK. Samples were collected in accord-
ance with ethical approval from the Office for Research 
Ethics Committees (N. Ireland) (Ethical approval number 
08/NIR03/15), and informed consent was obtained from 
all patients. RNA was extracted from pulp tissue (n = 12) 
and an ex vivo pulpitis model, using Maxwell RNA extrac-
tion kit (Promega Corporation). cDNA was prepared using 
the VILO Transcriptor First- Strand cDNA Synthesis Kit 
(Invitrogen). PCR reactions were performed using TaqMan 
specific primers and probes for CCL21 (Hs00171076_m1), 
MT1H (Hs00823168_g1) and AQP9 (Hs01033361_m1) 
(Thermo Fisher Scientific) as previously described (Al 
Natour et al., 2021). Changes in gene expression were 
analysed using the Mx3005P qPCR System (Agilent 
Technologies) and normalized to the housekeeping genes, 
glucuronidase- beta (GUSB) and β2- Microglobulin (B2M) 
(Thermo Fisher Scientific).
Ex vivo pulpitis model
An ex vivo pulpitis co- culture model of primary human 
dental pulp cells (DPCs) and THP- 1 macrophages was 
set up using a Transwell system (Corning Costar) as pre-
viously described (Rankin et al., 2020; Yonehiro et al., 
2012). DPCs obtained from three donors were derived 
by explant culture from third molar teeth as previously 
described (About et al., 2000; El Karim et al., 2016) and 
grown in minimal essential medium with L- glutamine sup-
plemented with 10% Foetal bovine serum (FBS), 100 UI/ml 
penicillin and 100 mg/ml streptomycin. THP- 1 cells were 
grown in Roswell Park Memorial Institute medium (RMPI- 
1640) media supplemented with 10% FBS and differenti-
ated into macrophages by incubation in 100  nM phorbol 
12- myristate 13- acetate (PMA) (Sigma Aldrich) for 24 h. 
DPCs were seeded in the lower Transwell chamber at a 
density of 2 × 105 cells per well. THP- 1 cells were seeded 
in the upper chamber at the density of 1  ×  105 cells per 
well and differentiated into macrophages in the presence 
of 100 nM phorbol 12- myristate 13- acetate (PMA) (Sigma 
Aldrich). The upper and lower chambers were assembled 
as a co- culture, separated by 0.4 mm pore diameter mem-
brane and co- cultured cells were then treated with 1 μg/ml 
ultrapure E. coli LPS (Sigma Aldrich) with or without the 
compound/drug of interest for 24 h.
MTT assay
DPCs and THP- 1 were seeded in 96- well plates at a density 
of 3 × 104/ml and treated with control media or predicted 
compound at different concentrations for 24 h. MTT assay 
was performed by adding 10 μl MTT solution to each well 
for 2 h at 37°C, media was aspirated, wells were air- dried 
for 10  min and 200  μl DMSO was added and incubated 
at 37°C for a further 10 min. Sample optical density was 
measured at 510  nm using a Tecan GENios microplate 
reader (Tecan).
ELISA and Luminex Multiplex assays
The cytokines IL8, IL6, the chemokine (C- C motif) ligand 
21(CCL21) and MMP9, were simultaneously measured from 
co- culture supernatant in the ex vivo pulpitis model using a 
magnetic Luminex assay kit and ELISA (R&D Systems). To 
establish a working concentration, the effect of each drug on 
DPCs treated with LPS was assessed by measurement of IL8 
using Duoset ELISA (R&D Systems).
Statistical analysis
Data are presented and analysed as mean  ±  standard de-
viation (SD) using GraphPad Prism software, version 5.0 
(GraphPad Software, Inc.). Means were compared using the 
t- test or ANOVA followed by a Bonferroni or Dunnet post- 
test with the level of significance set at p ≤ .05.
RESULTS
Differential gene expression and ssCMap 
output
In total 53 619 probes were identified in the data sets and 
this number was used to calculate the cut- off point 1/N 
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(p = .000018) for differential gene expression analysis. This 
cut- off p- value was aimed to control the expected number 
of false- positive DEGs as 1. Using this cut- off point a gene 
signature (154 genes, eFDR = 1/154 ≈ 0.6%) was created, 
which resulted in the identification of 76 compounds using 
ssCMap (Figure S1A). A longer gene signature (281 genes) 
was created using a cut- off point of p = .0001, for which 
the ssCMap revealed 232 compounds that could modulate 
these genes (Figure S1B). The longer gene signature was 
based on a slightly more relaxed p- value cut- off, which 
controlled the expected number of false- positive DEGs to 
about 5, resulting in an overall eFDR ≈ 5/281 ≈ 2% for this 
set of DEGs.
To identify potential biomarkers, a list of genes with 
log2 fold change greater than 0.5859 (1.5- fold change) 
was created (Table 1). The 1.5- fold change was chosen 
to prioritize genes with low but statistically significant 
fold change. These included cytokines that were previ-
ously suggested as potential biomarkers for pulpitis such 
as Interleukin 8 (IL8), Interleukin 6 (IL6) and Matrix 
Metalloproteinase 9 (MMP9) (Rechenberg et al., 2016). In 
addition, novel genes including chemokine (C- C motif) li-
gand 21 (CCL21), metallothionein 1H (MT1H), aquaporin 
9 (AQP9), FBJ murine osteosarcoma viral oncogene ho-
molog B (FOSB), peptidase inhibitor 3, skin- derived (PI3), 
metallothionein 1G (MT1G), C- type lectin domain family 
4, member E (CLEC4E), serine dehydratase (SDS), selec-
tin E (SELE), cholesterol 25- hydroxylase (CH25H) and a 
triggering receptor expressed on myeloid cells 1 (TREM1) 
were identified.
Validation of selected novel pulpitis genes
For validation, the top three novel genes CCL21, MT1H and 
AQP9 were selected for qPCR quantification in the dental 
pulps of sound and carious teeth with a clinical diagnosis of 
symptomatic irreversible pulpitis. AQP9, MT1H and CCL21 
were all expressed in the dental pulp tissue and their expres-
sion is upregulated in samples of irreversible pulpitis com-
pared to the healthy pulp. Expression of AQP9 is significantly 
higher compared to MT1H (p < .05) and CCL21 (p < .001) in 
dental pulps with irreversible pulpitis (Figure 1).
Compounds selection and their effects on 
cell viability
The ssCMap identified 232 compounds for the long query and 
79 for the short query that could potentially modulate gene 
signature. Compounds were selected based on their high-
est connection scores. Fluvastatin and dequalinium chloride 
were the two compounds identified by both queries with the 
highest connection scores and therefore selected for experi-
mental validation. Fluvastatin is a Hydroxymethylglutaryl- 
CoA (HMG- CoA) reductase inhibitor (statin) class of drugs, 
while dequalinium chloride is Quaternary ammonium cation 
(Table 2). MTT assay showed that fluvastatin, had no effect 
on DPCs or THP- 1 macrophages viability at any of the con-
centrations tested (Figure 2). However, dequalinium chloride 
significantly reduced cell viability at a higher concentration 
(p < .05) (Figure 2).
T A B L E  1  List of genes with a log2 fold change greater than 0.5859 (1.5- fold change) selected as potential biomarkers
GPL96_ID Gene symbol Gene name Log2 fold change p- value Regulation
202859_x_at IL8 Interleukin 8 1.241889632 6.74E- 05 1
204606_at CCL21 Chemokine (C- C motif) ligand 21 1.053933825 6.89E- 10 1
206461_x_at MT1H Metallothionein 1H 1.032697802 1.36E- 06 1
205568_at AQP9 Aquaporin 9 0.935287545 8.06E- 05 1
203936_s_at MMP9 Matrix metallopeptidase 9 0.89000635 5.57E- 08 1
202768_at FOSB FBJ murine osteosarcoma viral oncogene 
homolog B
0.84370843 5.03E- 07 1
203691_at PI3 Peptidase inhibitor 3, skin- derived 0.783932029 6.44E- 13 1
204745_x_at MT1G Metallothionein 1G 0.778623636 2.34E- 10 1
219859_at CLEC4E C- type lectin domain family 4, member E 0.748959137 3.9E- 05 1
205695_at SDS Serine dehydratase 0.747035464 6.59E- 06 1
206211_at SELE Selectin E 0.736467219 3.43E- 09 1
206932_at CH25H Cholesterol 25- hydroxylase 0.733972379 1.35E- 08 1
219434_at TREM1 Triggering receptor expressed on myeloid 
cells 1
0.706776916 3.61E- 06 1
205207_at IL6 Interleukin 6 (interferon, beta 2) 0.671590863 4.42E- 07 1
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Effect of selected compounds on 
pulpitis biomarkers
In preliminary work to determine the working concentra-
tion of the compounds, their ability to reduce IL8 levels 
in LPS treated DPCs was measured by ELISA. Of the 
concentrations tested, 10 µM fluvastatin and 100 nM de-
qualinium chloride reduced IL8 levels (Figure S2). Next, 
the effect of fluvastatin and dequalinium chloride on pul-
pitis biomarkers protein and gene expression was exam-
ined using the ex vivo pulpitis model. As shown in Figure 
3, fluvastatin treatment resulted in a significant reduc-
tion in the levels of IL8, IL6, CCL21 (p < .001), MMP9 
(p  <  .05) and gene expression of AQP9 (p  <  .001). 
Dequalinium chloride resulted in a significant reduction 
in AQP9 gene expression (p  <  .001) and reduced IL8, 
IL6, MMP9 and MT1H, but the reduction was not signifi-
cant (Figure 4).
DISCUSSION
The current description of pulpitis as reversible/irreversible has 
become questionable, given advances in minimally invasive 
vital pulp treatments (VPT) and the evidence that maintenance 
of pulp vitality is possible in teeth with cariously exposed pulp 
and those with signs and symptoms of irreversible pulpitis 
(Cushley et al., 2019, 2020; Li et al., 2019). The success of min-
imally invasive VPT requires parallel development in diagno-
sis, with novel treatments for pulpitis (Duncan et al., 2019). In 
line with this, the present study employed comprehensive gene 
expression analysis and bioinformatics approaches to identify 
biomarkers as well as compounds that could treat pulpitis. The 
results of this study showed that using the above methods, a 
disease- specific gene signature for irreversible pulpitis was cre-
ated, and this gene signature could be modified indicating the 
possibility of reversing the disease, at the level of in silico mod-
elling and in an ex vivo pulpitis model.
F I G U R E  1  Expression of the 
novel genes AQP9, MT1H and CCL21, 
validated in teeth clinically diagnosed with 
irreversible pulpitis (IRP). The expression 
of the genes was determined using qPCR 
and fold change was calculated in relation 
to healthy pulps. AQP9 is significantly 
upregulated in dental pulp with IRP 
compared to MT1H and CCL21. Unpaired 



























































T A B L E  2  Top candidate drugs identified by ssCMap using two gene queries. The connection sores show the correlation of the drugs with the 
input gene signature. Negative scores indicate a negative correlation, that is the input genes are downregulated when treated with the particular 
drug. Drugs with the highest connection scores were selected for laboratory validation. Fluvastatin and dequalinium chloride were among the top 
candidates for both queries
Connection scores Set scores p value Drug class and effect
Fluvastatin −5.28287a −0.186540827 .0001 HMG- CoA reductase inhibitor, anti- lipemic, 
anti- inflammatory−3.838490829b −0.183546829 .0001
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The gene signature revealed genes previously shown to 
be upregulated in irreversible pulpitis such as IL8, IL6 and 
MPP9 (Rechenberg et al., 2016), which confirms the valid-
ity of this approach and provides further evidence for these 
genes as pulpitis biomarkers. In addition, three novel genes 
including CCL21, M1H and AQP9 were also identified and 
validated using qPCR of dental pulps with the clinical diag-
nosis of irreversible pulpitis.
The dental pulp is enclosed within rigid dentinal walls 
creating low interstitial compliance, which was traditionally 
considered to limit the ability of the pulp to recover from 
severe inflammation (Yu & Abbott, 2007). During pulpitis 
the pulpal fluid volume increases, causing the tissue pres-
sure to increase and leading to compression of blood ves-
sels and subsequent ischaemia and necrosis (Heyeraas & 
Berggreen, 1999). Therefore, tight regulation of pulpal fluid 
F I G U R E  2  Effect of the selected 
compounds fluvastatin and dequalinium 
chloride on the viability of dental pulp 
cells (DPCs) and THP- 1 macrophages. 
Fluvastatin had no significant effects 
on the viability of DPCs (a), or THP- 1 
macrophages (c) at any of the concentrations 
tested. Dequalinium chloride significantly 
reduced both DPCs (b) and THP- 1 
macrophage (d) viability at 10 μM 















































































F I G U R E  3  Effects of Fluvastatin 
on pulpitis biomarkers measured using 
a multiplex assay for IL8, IL6, MMP9, 
CCL21 and qPCR for AQP9 and MT1H. 
Biomarkers were significantly upregulated 
with LPS treatment. Fluvastatin significantly 
reduced, IL8, IL6, CCL21, MMP9, AQP9 
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dynamics is important in the resolution of pulpitis. Cellular 
fluid movement is regulated by aquaporins (AQP), the cell 
membrane- embedded proteins that facilitate water move-
ments by increasing membrane water permeability and water 
flux in response to osmotic gradients (Agre & Kozono, 
2003). Of these, AQP9 has previously been found to be asso-
ciated with brain oedema (Badaut et al., 2014). In the current 
study, AQP9 was highly expressed in irreversible pulpitis, in 
which oedema is also often reported (Trowbridge, 1981). It is 
likely that increased expression of AQP9 in irreversible pul-
pitis contributes to the development of oedema and increase 
pulpal fluid volume by facilitating water movement. AQP9 
also plays a critical role in leukocyte and dendritic cells func-
tion during systemic inflammation (De Santis et al., 2018; 
Matsushima et al., 2014) and its level is upregulated in pa-
tients with infectious endocarditis (Thuny et al., 2012). These 
suggested roles in oedema and response to infection make 
AQP9 an important novel biomarker for pulpitis. Indeed the 
results of this study, which demonstrated higher expression 
of AQP9 compared to other novel biomarkers for pulpitis and 
its consistent reduction by both fluvastatin and dequalinium 
chloride in the ex vivo pulpitis models further support this 
notion.
Another novel gene identified in this study was MT1H, 
which belongs to a family of small metal- binding cellular 
proteins that bind to heavy metals such as zinc (Kalinowski 
& Richardson, 2010). MT1H plays a role in regulating cel-
lular zinc homeostasis as well as other functions, including 
neuroprotection, anti- inflammatory and defence against 
oxidative damage (Chung et al., 2009; Coyle et al., 2002). 
CCL21 is another novel gene identified in the study. It is a 
potent pro- inflammatory chemokine that regulates dendritic 
cell migration and has been implicated in various chronic 
inflammatory pain conditions, including rheumatoid arthri-
tis and neuropathic pain (Biber et al., 2011; Pickens et al., 
2012). In the central nervous system, CCL21 expression is 
increased in damaged neurons, leading to increased microg-
lial P2X4 expression (Biber et al., 2011), a finding that is 
likely to be replicated in the dental pulp as highly innervated 
tissue. However, the expression of both MT1H and CCl21 
in irreversible pulpitis in this study was variable and the dif-
ference between healthy and diseased samples did not reach 
significance, suggesting the inherited variability in pulpitis 
diagnosis that rely on subjective patients symptoms (Mejàre 
et al., 2012).
Another interesting finding of this study was the iden-
tification of compounds that could modify the gene sig-
nature associated with irreversible pulpitis and thereby 
potentially reverse the disease. Among the compounds 
identified, fluvastatin is a member of the 3- hydroxy- 3- m
ethyl- glutaryl– coenzyme- A (HMG- CoA) reductase in-
hibitors (statins) drug class that function by slowing the 
production of cholesterol. In addition to their classic func-
tion, statins have well- documented anti- inflammatory ef-
fects (Björkhem- Bergman et al., 2010; Leung et al., 2003). 
Among the stains, simvastatin has been shown to reduce 
F I G U R E  4  Effects of Dequalinium 
chloride on pulpitis biomarkers measured 
from co- culture using a multiplex assay and 
ELISA for IL8, IL6, MMP9, CCL21 and 
qPCR for AQP9 and MT1H. Biomarkers 
were upregulated with LPS treated. 
Dequalinium chloride (Deq) significantly 
reduced AQP9 but the reduction was not 
significant for IL8, lL6 MMP9, CCL21 
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the production of cytokines in the dental pulp (Jung et al., 
2017) and to enhance odontogenic differentiation of den-
tal pulp stem cells (Miyazawa et al., 2015; Okamoto et al., 
2009). A biphasic calcium phosphate cement containing 
simvastatin is recently developed as novel pulp capping 
material (Chang et al., 2020). The findings of the current 
ex vivo study, that fluvastatin reduced inflammatory cyto-
kines associated with irreversible pulpitis, provide further 
support for the anti- inflammatory properties of statins and 
their repurposing for treatment of pulpitis.
Dequalinium chloride was also identified by ssCMap as 
a compound highly correlated with the irreversible pulpitis 
gene signature. It is a bis- quaternary ammonium compound 
with a broad- spectrum antimicrobial activity against Gram- 
positive and Gram- negative bacteria, yeasts and protozoa 
(Tischer et al., 2012) and currently used as a topical treat-
ment for vaginal infections (Mendling et al., 2016). Although 
dequalinium chloride was not as effective as fluvastatin in 
reducing all the cytokines tested in this study, its broad anti-
microbial effect is very advantageous in the context of caries- 
induced pulp inflammation, as control of infection is key to 
a successful vital pulp treatment (Bjørndal et al., 2019; ESE, 
2019). In fact, antimicrobial activity for fluvastatin has also 
been demonstrated (Jerwood & Cohen, 2008). Therefore, the 
identification of compounds with antimicrobial activity to 
treat pulpitis gives confidence to the ssCMap approach, as 
pulpitis is primarily a bacterial- induced disease. Although 
reduction of cytokines is a desirable treatment outcome, con-
trol of bacterial infection is essential and further studies to 
evaluate antimicrobial effects against endodontic pathogens 
are warranted. It is essential also that the anti- inflammatory 
and antimicrobial effect of these drugs be investigated in vivo 
to validate these ex vivo findings.
The ssCMap is a very useful tool for repurposing drugs al-
ready licenced for human use and therefore reduces the need 
for the lengthy drug discovery process, however, the method 
is not without limitations. For instance, the gene signature 
created is not inclusive of all differentially expressed genes 
as many have not been cloned or their function identified yet, 
therefore, a future analysis may reveal further biomarkers and 
more compounds as potential therapeutics for pulpitis. The 
limited number of GEO datasets available to be included in 
this study is also another limitation as likely a larger number 
of data sets may result in different gene signatures and conse-
quently additional compounds. Nevertheless, the genes and the 
compounds identified and validated in this study are relevant 
to pulpitis disease pathophysiology and potential treatment.
CONCLUSION
ssCMap and gene expression analysis can be successfully 
used to identify biomarkers and compounds for the treatment 
of irreversible pulpitis. AQP9, MT1H and CCL21 were 
identified and validated as novel biomarkers for pulpitis. 
Fluvastatin and dequalinium chloride identified by the ssC-
Map as potential therapeutics for pulpitis, reduced selected 
pulpitis biomarkers in an ex vivo pulpitis model. Reduction 
of biomarkers with fluvastatin and dequalinium chloride 
suggest a potential use as pulp capping/dressing materials 
in treating pulpitis, and their in vivo validation could reveal 
novel therapeutic applications.
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